MPP delivered a statement on the Global AIDS Strategy 2026-2031 at the 57th meeting, UNAIDS Programme Coordinating Board, 16-18 December 2025.

—

Agenda Item 4: The Global AIDS Strategy 2026–2031 (Documents: UNAIDS/PCB (57)/25.30)

MPP statement

Delivered by Mila Maistat

Thank you, Chair.

The Medicines Patent Pool commends UNAIDS for the leadership in developing the Global AIDS Strategy 2026–2031 and welcomes it.

Access to medicines is intrinsically linked to the Strategy’s priorities. It is fundamental to realising the human right to the highest attainable standard of health, to creating an enabling environment for the HIV response, and to ensuring its sustainability and resilience.

For more than a decade, with the financial support from Unitaid, voluntary licensing through the Medicines Patent Pool has played a central role in expanding access to HIV medicines in low- and middle-income countries. Through MPP’s public health–oriented licensing model, more than 24 million people across 148 countries, including many lower- and upper-middle-income countries, have gained access to WHO-recommended, quality-assured and affordable generic HIV medicines. This includes essential treatment combinations such as TLD, as well as critical paediatric formulations, including paediatric DTG and ALD fixed-dose combination. This progress was made possible through the ongoing support of Unitaid, collaborations with UNAIDS, WHO, governments, manufacturers, Global Fund, communities, and many other partners at global and national levels.

In the context of the ongoing funding constraints on the one hand, and continued innovation—such as existing and upcoming long-acting formulations—on the other, voluntary licensing and technology transfer on public health–driven terms and conditions, manufacturing capacity building and local production are becoming ever more critical to enabling equitable and timely access to needed medicines and other health products.

MPP remains firmly committed to continued collaboration with UNAIDS, WHO, Member States, communities, manufacturers, procurement agencies, and other stakeholders to accelerate and expand access to medicines for prevention and treatment of HIV, co-infections and other diseases for people in low- and middle-income countries.

Thank you